Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727 is registered in ClinicalTrials.gov with Keryx Biopharmaceuticals as lead sponsor.

NCT NCT04523727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04523727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
Lead sponsor
Keryx Biopharmaceuticals
Phase
Phase 3
Overall status
Suspended
Start date
June 16, 2022
Completion date
October 31, 2027
Enrollment
45 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia related to chronic kidney disease